Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*

By Herschorn Sender   Heesakkers John   Castro-Diaz David   Wang Joseph T.   Brodsky Marina   Guan Zhonghong  

Current Medical Research and Opinion, Vol. 24, Iss. 12, 2008-12 ,pp. : 3513-3521

Informa Healthcare

Access to resources Recommend Favorite

Onset of efficacy of tolterodine extended release in patients with overactive bladder

By Sussman David O.   Kraus Stephen R.   Carlsson Martin   Guan Zhonghong  

Current Medical Research and Opinion, Vol. 23, Iss. 4, 2007-04 ,pp. : 777-781

Informa Healthcare

Access to resources Recommend Favorite

Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder

By  

BJU INTERNATIONAL, Vol. 116, Iss. 3, 2015-09 ,pp. : 443-449

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom

By Hart Warren Mark   Abrams Paul   Munro Vicki   Retsa Peny   Nazir Jameel  

Journal of Medical Economics, Vol. 16, Iss. 10, 2013-10 ,pp. : 1246-1254

Informa Healthcare

Access to resources Recommend Favorite

Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence

By Rogers Rebecca G.   Bachmann Gloria   Scarpero Harriette   Jumadilova Zhanna   Sun Franklin   Morrow Jon D.   Guan Zhonghong   Bavendam Tamara  

Current Medical Research and Opinion, Vol. 25, Iss. 9, 2009-09 ,pp. : 2159-2165

Informa Healthcare

Access to resources Recommend Favorite